Payment overview · 2025
General Payments
$654.95
32 reported records · 13 companies
Healthcare provider profile · identity verified
Carolyn L Ebert, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHESANING, MI · NPI 1588878201
Verified facts
What the public records show
CMS Open Payments records show Carolyn L Ebert, MD received $654.95 in general payments during 2025 across 32 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Tymlos.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $143.28 | 21.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.22 | 15.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $98.39 | 15.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.74 | 10.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.63 | 10.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.29 | 8.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.90 | 3.3% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $20.06 | 3.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.02 | 2.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.82 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.05 | 2.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.57 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.98 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $654.95 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143.28 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $98.39 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.41 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.63 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.29 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.29 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 371 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 261 | 42 |
| Omeprazole | Omeprazole | 229 | 75 |
| Metformin Hcl | Metformin Hcl | 227 | 68 |
| Gabapentin | Gabapentin | 212 | 45 |
| Losartan Potassium | Losartan Potassium | 204 | 69 |
| Lisinopril | Lisinopril | 201 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 47 |
| Meloxicam | Meloxicam | 152 | 53 |
| Simvastatin | Simvastatin | 131 | 37 |
| Potassium Chloride | Potassium Chloride | 112 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 33 |
| Clonazepam | Clonazepam | 110 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 38 |
| Furosemide | Furosemide | 103 | 32 |
| Alprazolam | Alprazolam | 93 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 33 |
| Lorazepam | Lorazepam | 92 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 21 |
| Eliquis | Apixaban | 85 | 20 |
| Atenolol | Atenolol | 82 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 78 | 12 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Famotidine | Famotidine | 73 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 20 |
| Ozempic | Semaglutide | 65 | 11 |
| Pregabalin | Pregabalin | 64 | 14 |
| Bupropion Xl | Bupropion Hcl | 62 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 21 |
| Montelukast Sodium | Montelukast Sodium | 57 | 17 |
| Allopurinol | Allopurinol | 55 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 16 |
| Carvedilol | Carvedilol | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 16 |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Methylprednisolone | Methylprednisolone | 42 | 38 |
| Spironolactone | Spironolactone | 41 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Trazodone Hcl | Trazodone Hcl | 37 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Prednisone | Prednisone | 35 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Buspirone Hcl | Buspirone Hcl | 29 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 15 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Nystatin | Nystatin | 17 | 14 |
| Temazepam | Temazepam | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Diazepam | Diazepam | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $654.95 · 32 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, EVENITY, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TERIPARATIDE, Tymlos, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error